Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CD22 | P20273 | 2/20 | 0.36 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.36 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240372 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL29397247 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL13191000 | 1.00 | NANP (0.73) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL30887281 | 0.87 | NANP (0.69) | NANPL3MBTL1CD22SIGLEC7SELL | |
| SCHEMBL27240262 | 0.87 | NANP (0.69) | NANPL3MBTL1CD22SIGLEC7SELL | |
| Sialic Acid SCHEMBL29668416 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| Sialic Acid SCHEMBL19718196 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| Sialic Acid SCHEMBL3156058 | 0.86 | NANP (0.77) | NANPL3MBTL1SIGLEC7SELLSELP | |
| SCHEMBL420656 | 0.86 | NANP (0.67) | NANPL3MBTL1SELLSELP | |
| SCHEMBL29390472 | 0.86 | NANP (0.67) | NANPL3MBTL1SELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116773710-A | Kit for covering metabolome and metabolic flow of multiple metabolites and use method | 清华大学 | 2023-09-19 | — | — | CN | claimed |
| CN-116323930-A | Cell production of sialylated di-and/or oligosaccharides | 因比奥斯公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2023057386-A1 | COMPOSITIONS FOR PREVENTING AND/OR TREATING DEMYELINATION | MJN U.S. HOLDINGS LLC (US) | 2023-04-13 | — | — | WO | claimed |
| CN-113624862-B | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2023-04-07 | — | — | CN | claimed |
| EP-4003365-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | Lifescience AS (NO) | 2022-06-01 | — | — | EP | claimed |
| WO-2022006503-A2 | METHODS TO GLYCOENGINEER PROTEINS | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-06 | — | — | WO | claimed |
| CN-113624862-A | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2021-11-09 | — | — | CN | claimed |
| WO-2021019295-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | REMMEREIT JAN (NO) | 2021-02-04 | — | — | WO | claimed |
| CN-104736694-B | CRZ1 mutant fungal cells | 默沙东公司 | 2020-08-11 | — | — | CN | claimed |
| US-9328367-B2 | Engineered lower eukaryotic host strains for recombinant protein expression | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| US-20140024812-A1 | ENGINEERED INTRACELLULAR SIALYLATION PATHWAYS | THE UNIVERSITY OF WYOMING (US) | 2014-01-23 | — | — | US | claimed |
| US-8546105-B2 | Engineering intracellular sialylation pathways | THE UNIVERSITY OF WYOMING (US) | 2013-10-01 | — | — | US | claimed |
| WO-2013062940-A1 | ENGINEERED LOWER EUKARYOTIC HOST STRAINS FOR RECOMBINANT PROTEIN EXPRESSION | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2013019625-A2 | METHODS OF USING A BACTERIAL GLCNAC-6-P 2'-EPIMERASE TO PROMOTE SIALYLATION OF GLYCOCONJUGATES | THE UNIVERSITY OF WYOMING (US) | 2013-02-07 | — | — | WO | claimed |
| US-20130029413-A1 | Methods of Using a Bacterial GlcNAc-6-P 2'- Epimerase to Promote Sialylation of Glycoconjugates | UNIVERSITY OF WYOMING (US) | 2013-01-31 | — | — | US | claimed |
| US-20120264928-A1 | THERAPEUTIC PHARMACEUTICAL AGENT FOR DISEASES ASSOCIATED WITH DECREASE IN FUNCTION OF GNE PROTEIN, FOOD COMPOSITION, AND FOOD ADDITIVE | JAPAN HEALTH SCIENCES FOUNDATION (JP) | 2012-10-18 | — | — | US | claimed |
| US-20110229931-A1 | Engineering intracellular sialylation pathways | THE UNIVERSITY OF WYOMING | 2011-09-22 | — | — | US | claimed |
| EP-0524143-B1 | Process of preparation of activated sialic acids | CIBA GEIGY AG (CH) | 1997-12-10 | — | — | EP | claimed |
| US-5334514-A | Reacting sialic acid with cytidine 5*-triphosphate in presence of cell extract of microorganism having cytidine 5*-monophospho-N-acetylneuraminic acid synthetase activity | CIBA VISION CORPORATION | 1994-08-02 | — | — | US | claimed |
| EP-0524143-A1 | Process of preparation of activated sialic acids | CIBA-GEIGY AG (CH) | 1993-01-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264928-A1 | THERAPEUTIC PHARMACEUTICAL AGENT FOR DISEASES ASSOCIATED WITH DECREASE IN FUNCTION OF GNE PROTEIN, FOOD COMPOSITION, AND FOOD ADDITIVE | GNE, ENGASE, GNPDA1 | NANP 27/4885L3MBTL1 4159/4885CD22 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.